Selpercatinib for Thyroid Cancer User Reviews
Brand names: Retevmo
See also:
Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
More about selpercatinib
- Check interactions
- Compare alternatives
- Reviews (5)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
"Diagnosed with MTC 8/2020. Rx initiated 11/2020. One month later, primary nodule in thyroid and larger nodules in lung decreased in size by ~50%. Little or no reduction subsequently, but calcitonin and CEA continued to drop until in normal range (big drop first few months!). Started with 320 mg, reduced after 3-4 months to 240 mg, then to 160 mg (80 mg 2x daily). Condition stable as of 01/2023. Early side effects were abdominal pain and slight leg swelling in one leg. Pain went away after dosage reduced. Swelling diminished. Doctor says some from initial trial stable four years on. I can’t find any data, though, other than for trials that led to initial approval, which only refer to efficacy after 6 months. I wish I could find more new data, but am very happy with results to date, and I’m hoping stability continues … UNTIL A CURE IS FOUND! Keep working, researchers. You don’t know us, but we’re counting on you. Thank you."